Global Perspectives: Current and Future Management of Breast Cancer 2022
Practice changes and a look to the future from ESMO 2022 and beyond in triple-negative breast cancer, HR+, HER2– early and metastatic breast cancer.
FACULTY CO-CHAIR
Nadia Harbeck, MD, PhD
Ludwig-Maximilians-University of Munich – Breast Center, Germany
FACULTY CO-CHAIR
Joyce A. O’Shaughnessy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US
Faculty Members
Mark Pegram, MD
Stanford Womens Cancer Center, Palo Alto, CA, USA
Hope Rugo, MD, FASCO
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
William Gradishar, MD
Northwestern Medical Group, chicago, IL, USA
Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Guy Jerusalem, MD, PhD
University of Liège, Belgium
Javier Cortes, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
Valentina Guarneri, MD, PhD
University of Padua, Padova, Italy
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Current and Emerging Biomarkers and Testing Methodologies in BC
- Current and New Treatments in HER2+ Early BC
- Advances in HER2+ Metastatic Breast Cancer (mBC)
- Current and Emerging Approaches in HR+, HER2– Early BC
- Therapeutic Horizons in HR+, HER2– mBC
- Maximizing Potential Targeting of HER2 in HER2-Low mBC
- Advances in Early and Metastatic Triple-Negative Breast Cancer (TNBC)
